WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Prostate Cancer Efficacy Endpoints_v5, Anatomical region instantiated by -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, New Lesion Count identified in Anatomical location, Non-opiate Administration measured at Start Date, Target lesion evaluated by Quantitative assessment, OVERALL RESPONSE derived from Sponsor specified Response Criteria (e.g. RECIST), Functional Status Impairment masured with Functional Status Assessment Tool, Sum of longest diameters (SLD) has component LD (axial plane) for target lesion, Time-To-Event end points include Time to initiation of chemotherapy, - CR - PR differentiated into Confirmed Response, -Complete Response (CR) -Non-CR/non-PD -Not evaluated -Not all evaluated -Non-PD -PD -Unequivocal PD -Any summarized into OVERALL RESPONSE, T U M O R R E S P O N S E is assessed with -MRI -CT, New Lesion Count identified on Protocol Specified Dates, Progression Free Survival (PFS) includes Radiographic Progression Free Survival (rPFS), Protocol Specified Dates include Confirmation Scan Date, Non-target lesion evaluated by Qualitative Assessment, New lesion identified by Organ specific lesion ID, OVERALL RESPONSE have response options -SD -PD -NE (inevaluable), Circulating Tumor Cells (CTC) measured in Date, Time to opiate use derived from Opiate Administration, LD (axial plane) for target lesion measured in mm